FDA advisory panel recommends six peptides for the compounding list, over staff objections
At its July 23–24, 2026 meeting the Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List and against emideltide (DSIP). The vote changes nothing yet.
Published October 3, 2026 · Twenty Residues editorial
What the record establishes
- FDA's meeting page confirms the committee met July 23–24, 2026 to evaluate nominated bulk substances for the 503A Bulks List, and lists the seven substances and their proposed uses (e.g. BPC-157 for ulcerative colitis, KPV and TB-500 for wound healing, MOTS-c for obesity and osteoporosis, Epitalon for insomnia, Semax for cerebral ischemia, migraine, and trigeminal neuralgia).
- Reported tallies (secondary): BPC-157, KPV, and TB-500 each 8–6 with one abstention in favor; MOTS-c 7–5 with two abstentions in favor; Semax and Epitalon in favor by similar margins; emideltide rejected 7–6 with one abstention.
- Reported (secondary): FDA's own reviewers had recommended against including all seven.
- A favorable committee vote is advisory. Adding a substance to the 503A list requires FDA to accept the recommendation and complete notice-and-comment rulemaking. As of this writing none of the seven is on the list.
What it does not establish
- The vote is not an approval of any peptide for any use, and does not make compounding them legal today.
- A recommendation for the bulks list is a judgment about whether pharmacists may compound a substance for individual prescriptions. It is not a finding that the substance works for the nominated use.
- The official vote record is not on FDA's meeting page as of our review. The tallies above come from reporting, and we grade them accordingly.
What would change this
FDA posting the official meeting minutes or vote summary, a proposed rule adding any of the six, or a public FDA statement declining to follow the committee.
The open question
An advisory panel voted narrowly to let pharmacists compound peptides that FDA's own scientists said lacked human efficacy data. Is this access winning over evidence, or evidence standards failing to keep up with what people are already using? Both camps claim this vote.
We don't answer this one. Take it to wherever you argue about peptides, and send us the strongest case from either side.
Propose a question by emailor on the public record
Sources
- [1]July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (FDA)
primaryFDA meeting notice
- [2]AJMC — FDA Panel Backs 6 Peptides for Compounding (2026-07-31)
secondaryTrade-press report
- [3]NCPA — FDA advisory committee nominates six peptides for pharmacies to compound (2026-07-31)
secondaryTrade-association report